Satsuma Pharmaceuticals, Inc.
Satsuma Pharmaceuticals, Inc. (STSA): 1 pipeline candidate · ~11 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
10.8 months
D/E 0.15 · 0% dilution
Lead: Phase 3
1 candidate
N/A
N/A
A transparent, data-derived signal for Satsuma Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$19.5M
Quarterly Burn
$11.4M
Runway
10.8 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| sts101 | Phase 3 |
Frequently asked questions
How many drug candidates are in Satsuma Pharmaceuticals, Inc.'s pipeline?
Satsuma Pharmaceuticals, Inc. (STSA) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Satsuma Pharmaceuticals, Inc.'s lead drug candidate?
Satsuma Pharmaceuticals, Inc.'s most advanced tracked candidate is sts101 (Phase 3) for acute treatment of migraine.
What is Satsuma Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Satsuma Pharmaceuticals, Inc. has approximately 10.8 months of cash runway.
Who is the CEO of Satsuma Pharmaceuticals, Inc.?
John Kollins is the chief executive officer of Satsuma Pharmaceuticals, Inc. (STSA).
Get the full picture on Satsuma Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.